Immunic highlights 2023 accomplishments and upcoming milestones
– evidence for neuroprotective activity of vidofludimus calcium from phase 2 calliper interim analysis , consistent across the entire progressive multiple sclerosis population and all subtypes – – phase 3 ensure program in relapsing multiple sclerosis ongoing – – improvements in gut health demonstrated in phase 1b clinical trial of imu-856 in celiac disease – – expanded vidofludimus calcium patent portfolio with additional new patents granted; exclusivity protection expected into 2041 in the united states, unless extended further – – significantly strengthened balance sheet; cash runway extended into the third quarter of 2025 based on first tranch of january 2024 financing – new york , jan. 5, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2023 accomplishments and upcoming milestones. "the past year has been an extra-ordinarily productive and successful one for immunic, with key clinical data releases highlighting the uniqueness and enormous value potential of each of our two latest-stage clinical assets," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission